The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients


DEĞER S. M., ERTEN Y., Pasaoglu O. T., DERİCİ Ü., ALTOK K., Onec K., ...More

CLINICAL AND EXPERIMENTAL NEPHROLOGY, vol.17, no.3, pp.416-423, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 3
  • Publication Date: 2013
  • Doi Number: 10.1007/s10157-012-0725-0
  • Journal Name: CLINICAL AND EXPERIMENTAL NEPHROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.416-423
  • Keywords: FGF23, Dialysis, Iron therapy, Mineral metabolism, SACCHARATED FERRIC-OXIDE, FIBROBLAST-GROWTH-FACTOR, FGF23 ELEVATION, FIBROBLAST-GROWTH-FACTOR-23, HYPOPHOSPHATEMIA, OSTEOMALACIA, POLYMALTOSE, PHOSPHORUS, DISEASE, FGF-23
  • Dokuz Eylül University Affiliated: No

Abstract

Fibroblast growth factor 23 (FGF23) is an important counterregulatory hormone for phosphate homeostasis. Since it has been reported that iron administration induces hypophosphatemic osteomalacia by triggering FGF23 synthesis, we hypothesized that iron administration might lead to a further increase in FGF23, resulting in alterations to Ca-P metabolism in a stage 5 CKD population.